Spire Global price target raised to $18 from $12 at Canaccord
Canaccord raised the firm’s price target on Spire Global (SPIR) to $18 from $12 and keeps a Buy rating on the shares. The firm noted ...
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
JP Morgan highlights that Bluebird did achieve the milestone of its first Lyfgenia infusion during the quarter (and revenue recognition) and continues to increase the pace of patient starts (cell ...